Glimepiride is a third-generation sulfonylureas long-acting anti-diabetes drug. The main mechanism of its hypoglycemic effect is to stimulate the secretion by beta cells of the pancreas and partially increase the sensitivity of surrounding tissues. Its mechanism is through and sulfonyl urea receptors on the surface of the pancreatic beta cells (relative molecular mass of 6.5 x 104 protein), the receptor and ATP sensitive K + (KATP) channel phase coupling, pushing the KATP channel close, cause cell membrane depolarization, makes the open voltage dependent calcium channel, inhibit the synthesis of liver glucose.